Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

NK cells are primed by ANRS MVA(HIV)-infected DCs, via a mechanism involving NKG2D and membrane-bound IL-15, to control HIV-1 infection in CD4+ T cells.

Moreno-Nieves UY, Didier C, Lévy Y, Barré-Sinoussi F, Scott-Algara D; ANRS HIV Vaccine Network (AHVN).

Eur J Immunol. 2014 Aug;44(8):2370-9. doi: 10.1002/eji.201344149. Epub 2014 Jun 24.

2.

Natural killer cell responses to dendritic cells infected by the ANRS HIV-1 vaccine candidate, MVAHIV.

Cummings JS, Moreno-Nieves UY, Arnold V, Gilbert A, Yarbrough K, Didier C, Lévy Y, Barré-Sinoussi F, Scott-Algara D; ANRS HIV Vaccine Network (AHVN).

Vaccine. 2014 Sep 29;32(43):5577-84. doi: 10.1016/j.vaccine.2014.07.094. Epub 2014 Aug 13.

PMID:
25131736
3.

Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.

Climent N, Guerra S, García F, Rovira C, Miralles L, Gómez CE, Piqué N, Gil C, Gatell JM, Esteban M, Gallart T.

PLoS One. 2011;6(5):e19644. doi: 10.1371/journal.pone.0019644. Epub 2011 May 18.

4.

Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.

Brandler S, Lepelley A, Desdouits M, Guivel-Benhassine F, Ceccaldi PE, Lévy Y, Schwartz O, Moris A.

J Virol. 2010 May;84(10):5314-28. doi: 10.1128/JVI.02329-09. Epub 2010 Mar 10.

5.

Impaired CD4⁺ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients.

Glässner A, Eisenhardt M, Kokordelis P, Krämer B, Wolter F, Nischalke HD, Boesecke C, Sauerbruch T, Rockstroh JK, Spengler U, Nattermann J.

J Hepatol. 2013 Sep;59(3):427-33. doi: 10.1016/j.jhep.2013.04.029. Epub 2013 May 9.

PMID:
23665286
6.

Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.

Matusali G, Tchidjou HK, Pontrelli G, Bernardi S, D'Ettorre G, Vullo V, Buonomini AR, Andreoni M, Santoni A, Cerboni C, Doria M.

FASEB J. 2013 Jun;27(6):2440-50. doi: 10.1096/fj.12-223057. Epub 2013 Feb 8.

PMID:
23395909
7.

CD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination.

Jost S, Tomezsko PJ, Rands K, Toth I, Lichterfeld M, Gandhi RT, Altfeld M.

J Virol. 2014 Aug;88(15):8349-54. doi: 10.1128/JVI.00924-14. Epub 2014 May 14.

8.

A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.

Zhou H, Luo Y, Kaplan CD, Krüger JA, Lee SH, Xiang R, Reisfeld RA.

Blood. 2006 Apr 15;107(8):3251-7. Epub 2005 Dec 20.

9.
10.

HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing.

Richard J, Sindhu S, Pham TN, Belzile JP, Cohen EA.

Blood. 2010 Feb 18;115(7):1354-63. doi: 10.1182/blood-2009-08-237370. Epub 2009 Dec 14.

11.

MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.

Kutscher S, Allgayer S, Dembek CJ, Bogner JR, Protzer U, Goebel FD, Erfle V, Cosma A.

Gene Ther. 2010 Nov;17(11):1372-83. doi: 10.1038/gt.2010.90. Epub 2010 Jun 10.

PMID:
20535218
12.

Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis.

Tasca S, Tambussi G, Nozza S, Capiluppi B, Zocchi MR, Soldini L, Veglia F, Poli G, Lazzarin A, Fortis C.

AIDS. 2003 Nov 7;17(16):2291-8.

PMID:
14571180
14.

NKG2D signaling on CD8⁺ T cells represses T-bet and rescues CD4-unhelped CD8⁺ T cell memory recall but not effector responses.

Zloza A, Kohlhapp FJ, Lyons GE, Schenkel JM, Moore TV, Lacek AT, O'Sullivan JA, Varanasi V, Williams JW, Jagoda MC, Bellavance EC, Marzo AL, Thomas PG, Zafirova B, Polić B, Al-Harthi L, Sperling AI, Guevara-Patiño JA.

Nat Med. 2012 Feb 26;18(3):422-8. doi: 10.1038/nm.2683.

15.

Enhancement of natural killer and antibody-dependent cytolytic activities of the peripheral blood mononuclear cells of HIV-infected patients by recombinant IL-15.

Loubeau M, Ahmad A, Toma E, Menezes J.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Nov 1;16(3):137-45.

PMID:
9390564
16.

A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.

Offersen R, Nissen SK, Rasmussen TA, Østergaard L, Denton PW, Søgaard OS, Tolstrup M.

J Virol. 2016 Apr 14;90(9):4441-4453. doi: 10.1128/JVI.00222-16. Print 2016 May.

17.

HIV escape from natural killer cytotoxicity: nef inhibits NKp44L expression on CD4+ T cells.

Fausther-Bovendo H, Sol-Foulon N, Candotti D, Agut H, Schwartz O, Debré P, Vieillard V.

AIDS. 2009 Jun 1;23(9):1077-87. doi: 10.1097/QAD.0b013e32832cb26b.

PMID:
19424050
18.

Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway.

Westwood JA, Kelly JM, Tanner JE, Kershaw MH, Smyth MJ, Hayakawa Y.

J Immunol. 2004 Jan 15;172(2):757-61.

19.

Increased Natural Killer Cell Activation in HIV-Infected Immunologic Non-Responders Correlates with CD4+ T Cell Recovery after Antiretroviral Therapy and Viral Suppression.

Luo Z, Li Z, Martin L, Hu Z, Wu H, Wan Z, Kilby M, Heath SL, Huang L, Jiang W.

PLoS One. 2017 Jan 11;12(1):e0167640. doi: 10.1371/journal.pone.0167640. eCollection 2017.

20.

Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals.

Fogli M, Mavilio D, Brunetta E, Varchetta S, Ata K, Roby G, Kovacs C, Follmann D, Pende D, Ward J, Barker E, Marcenaro E, Moretta A, Fauci AS.

PLoS Pathog. 2008 Jul 11;4(7):e1000101. doi: 10.1371/journal.ppat.1000101.

Supplemental Content

Support Center